Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Overexpression of the wild type p73 gene in human bladder cancer

Abstract

p73, a first p53 relative, was recently identified and shown to be monoallelically expressed in a number of different human tissues. To determine the potential role of this gene in human bladder cancer, we investigated p73 expression levels, allelic expression patterns, and analysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and in seven bladder cancer cell lines. In a comparison between normal and tumor tissues using quantitative RT – PCR analysis, we found that p73 was overexpressed in 22/23 bladder cancers, sometimes as great as 20-fold. Allelic expression analysis using a C/T polymorphism in exon 2 and a newly identified T/C polymorphism in exon 5 revealed that p73 was biallelically expressed in both normal bladder and cancer tissues, suggesting that p73 is not imprinted in bladder tissue. Mutation screening of the p73 gene in bladder cancer DNAs using denaturing high-performance liquid chromatography analysis and DNA sequencing revealed no tumor-specific mutations in any coding exons of the p73 gene. These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE and Pellicer A. . 1994 Int. J. Cancer 56: 347–353.

  • Cordon-Cardo C and Reuter VE. . 1997 Semin. Diagn. Pathol. 14: 123–132.

  • Fujita J, Srivastava SK, Kraus MH, Rhim JS, Tronick SR and Aaronson SA. . 1985 Proc. Natl. Acad. Sci. USA 82: 3849–3853.

  • Goto K, Konomoto T, Hayashi K, Kinukawa N, Naito S, Kumazawa J and Tsuneyoshi M. . 1997 Mod. Pathol. 10: 428–437.

  • James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP and Cavenee WK. . 1988 Cancer Res. 48: 5546–5551.

  • Jost CA, Marin MC and Kaelin Jr WG. . 1997 Nature 389: 191–194.

  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P and Lelias JM. . 1997 Cell 90: 809–819.

  • Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG. . 1994 Cancer Res. 54: 531–538.

  • Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN and James CD. . 1998 Nucleic. Acids Res. 26: 1396–1400.

  • Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI and Liu W. . 1998a Cancer Res. 58: 2347–2349.

  • Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick GD, Polychronakos C, Smith DI and Liu W. . 1998b Oncogene 17: 1739–1749.

  • Mai M, Huang H, Reed C, Quan C, Smith JS, Alderete B, Jenkins R, Smith DI and Wanguo L. . 1998c Genomics 51: 359–363.

  • Miyazaki K, Funahashi K, Numata Y, Koshikawa N, Akaogi K, Kikkawa Y, Yasumitsu H and Umeda M. . 1993 J. Biol. Chem. 268: 14387–14393.

  • Naito S, Kotoh S, Koga H, Hasegawa S, Yamasaki T, Noma H and Kumazawa J. . 1996 Human Cell 9: 49–56.

  • Oefner PJ and Underhillo PA. . 1995 Am. J. Hum. Genet. 59: (Suppl) A266.

  • Parker SL, Tong T, Bolden S and Wingo PA. . 1996 CA Cancer J. Clin. 46: 5–27.

  • Reddy EP, Reynolds RK, Santos E and Barbacid MA. . 1982 Nature 300: 149–152.

  • Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW and Reuter VE. . 1993 J. Natl. Cancer Inst. 85: 53–59.

  • Takeda O, Homma C, Maseki N, Sakurai M, Kanda N, Schwab M, Nakamura Y and Kaneko Y. . 1994 Genes Chromos. Cancer 10: 30–39.

  • Tazaki H and Tachibana M. . 1988 Hum. Cell 1: 78–83.

  • Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voute PA, Delattre O, Laureys G, Van Roy N and Speleman F. . 1995 Eur. J. Cancer 31: 538–541.

  • Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith DI and Liu W. . 1998a Oncogene 17: 475–479.

  • Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI and Liu W. . 1998b Int. J. Oncol. 13: 101–105.

Download references

Acknowledgements

This work was supported by NIH Grant CA48031 (to DIS) and by the Mayo Foundation. AY is supported by the Prostate Cancer Program at Mayo.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yokomizo, A., Mai, M., Tindall, D. et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 18, 1629–1633 (1999). https://doi.org/10.1038/sj.onc.1202474

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202474

Keywords

This article is cited by

Search

Quick links